Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs neostigmine for postoperative pulmonary function in elderly abdominal surgery
ChiCTR2500110956Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex in postoperative pulmonary dysfunction (PPD) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Pulmonary function tests. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
postoperative pulmonary dysfunction (PPD)
Beyond the preview
Go deeper on ChiCTR2500110956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110956.